Barclays PLC Has $1.18 Million Stake in Adaptive Biotechnologies Co. (NASDAQ:ADPT)

Barclays PLC boosted its position in Adaptive Biotechnologies Co. (NASDAQ:ADPT) by 149.5% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 230,177 shares of the company’s stock after purchasing an additional 137,936 shares during the period. Barclays PLC owned 0.16% of Adaptive Biotechnologies worth $1,180,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. JTC Employer Solutions Trustee Ltd bought a new position in shares of Adaptive Biotechnologies during the third quarter valued at $26,000. Ashton Thomas Securities LLC acquired a new stake in Adaptive Biotechnologies in the third quarter valued at $34,000. MQS Management LLC bought a new position in Adaptive Biotechnologies during the 2nd quarter worth $36,000. Rothschild Investment LLC acquired a new position in Adaptive Biotechnologies during the 2nd quarter worth about $36,000. Finally, B. Riley Wealth Advisors Inc. acquired a new position in Adaptive Biotechnologies during the 2nd quarter worth about $49,000. 99.17% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

ADPT has been the subject of a number of analyst reports. Piper Sandler raised their price objective on Adaptive Biotechnologies from $6.00 to $7.00 and gave the stock an “overweight” rating in a research report on Monday, November 11th. BTIG Research raised their price target on shares of Adaptive Biotechnologies from $8.00 to $9.00 and gave the stock a “buy” rating in a report on Wednesday, December 18th.

Adaptive Biotechnologies Stock Down 2.3 %

Adaptive Biotechnologies stock opened at $6.29 on Monday. The stock has a market cap of $928.27 million, a P/E ratio of -4.69 and a beta of 1.49. The company’s 50 day moving average price is $5.65 and its two-hundred day moving average price is $4.78. Adaptive Biotechnologies Co. has a 52 week low of $2.28 and a 52 week high of $7.07.

Adaptive Biotechnologies Profile

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system.